CD34 and myelofibrosis: Ruxolitinib had a similar effect on HSPCs (CD34+CD38−CD45RA−) derived from the peripheral blood of 4 patients with myelofibrosis with high white blood cell counts, none of whom had previously received ruxolitinib or interferon.